Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
Obesity is a chronic metabolic disease affecting adults and children worldwide. It has become one of the leading causes of death, as obesity is known to be the main risk factor for a number of non-communicable diseases, in particular type 2 diabetes. This close relationship led to the connotation ‘diabesity', highlighting the fact that the majority of individuals with diabetes are overweight or obese. Until today the BMI is still used to classify overweight and obesity. Since reduced muscle mass is highly prevalent throughout the BMI range, the measurement of body composition is strongly recommended. Moreover, it is essential for monitoring the course of weight reduction, which is part of every effective anti-obesity treatment. Weight reduction can be achieved via different weight loss strategies, including lifestyle intervention (diet and exercise), pharmacotherapy, or bariatric surgery. However, not all of these strategies are suitable for all patients, and any further needs should be considered. Besides, attention should also be drawn to concomitant therapies. These therapies may promote additional weight gain and further trigger the deterioration of blood glucose control. Thus, therapeutic strategies are warranted, which can be easily used for the management of obese patients with type 2 diabetes to achieve their glycemic and weight loss goals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Obesity and T2D share key pathophysiological mechanisms and are both associated with increased risk for (i) metabolic complications [such as hypertension, dyslipidemia, obstructive sleep apnea (OSA) and metabolic-dysfunction associated steatotic liver disease (MASLD)] and (ii) cardiovascular disease [2,4].”
In the citing paper
“Obesity and T2D share key pathophysiological mechanisms and are both associated with increased risk for (i) metabolic complications [such as hypertension, dyslipidemia, obstructive sleep apnea (OSA) and metabolic-dysfunction associated steatotic liver disease (MASLD)] and (ii) cardiovascular disease [2,4].”
In the citing paper
“Obesity is the strongest risk factor for T2D and the obesity epidemic is heavily contributed to the rise of T2D prevalence, especially the increased rates of young-onset T2D [2].”
In the citing paper
“Obesity is the strongest risk factor for T2D and the obesity epidemic is heavily contributed to the rise of T2D prevalence, especially the increased rates of young-onset T2D [2].”
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Finucane, M. M., Stevens, G. A., Cowan, M. J., Danaei, G., Lin, J. K., Paciorek, C. J., Singh, G. M., Gutierrez, H. R., Lu, Y., Bahalim, A. N., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62037-5 · Cited by 4,050
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Self-citationGlobal burden of obesity in 2005 and projections to 2030
Kelly, T., Yang, W., Chen, C.-S., Reynolds, K., & He, J. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.102 · Cited by 3,319
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Obesity and Diabetes in the Developing World — A Growing Challenge
Hossain, P., Kawar, B., & El Nahas, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068177 · Cited by 2,200
Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet
Shai, I., Schwarzfuchs, D., Henkin, Y., Shahar, D. R., Witkow, S., Greenberg, I., Golan, R., Fraser, D., Bolotin, A., Vardi, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708681 · Cited by 2,143
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
Cited by
The Role of Obesity in Type 2 Diabetes Mellitus—An Overview
Chandrasekaran, P., & Weiskirchen, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031882 · Cited by 465
Diet and exercise in the prevention and treatment of type 2 diabetes mellitus
Magkos, F., Hjorth, M. F., & Astrup, A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0381-5 · Cited by 469
Gut microbiome and type 2 diabetes: where we are and where to go?
Sharma, S., & Tripathi, P. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.10.003 · Cited by 428
Marine Collagen as A Promising Biomaterial for Biomedical Applications
Lim, Y.-S., Ok, Y.-J., Hwang, S.-Y., Kwak, J.-Y., & Yoon, S. (2019) · Marine Drugs · doi:10.3390/md17080467 · Cited by 328
“Obesity is known to be the main risk factor not only for a number of non-communicable diseases like type-2 diabetes mellitus (T2DM), cardiovascular disease, hypertension, coronary heart disease, or certain types of cancers but also for diverse psychological problems and various physical disabilities [162].”
BackgroundErectile dysfunction and diabetes: A melting pot of circumstances and treatments
Defeudis, G., Mazzilli, R., Tenuta, M., Rossini, G., Zamponi, V., Olana, S., Faggiano, A., Pozzilli, P., Isidori, A. M., & Gianfrilli, D. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3494 · Cited by 285
Anti-Obesity Effects of Polyphenol Intake: Current Status and Future Possibilities
Boccellino, M., & D’Angelo, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165642 · Cited by 262
“If the trend is not reversed, by 2030, around 60% of the world’s population will be obese; therefore, according to the World Health Organization (WHO), obesity is currently a more severe world health problem than malnutrition [6].”
BackgroundFaecal virome transplantation decreases symptoms of type 2 diabetes and obesity in a murine model
Rasmussen, T. S., Mentzel, C. M. J., Kot, W., Castro-Mejía, J. L., Zuffa, S., Swann, J. R., Hansen, L. H., Vogensen, F. K., Hansen, A. K., & Nielsen, D. S. (2020) · Gut · doi:10.1136/gutjnl-2019-320005 · Cited by 255
Ciumărnean, L., Milaciu, M. V., Negrean, V., Orășan, O. H., Vesa, S. C., Sălăgean, O., Iluţ, S., & Vlaicu, S. I. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19010207 · Cited by 229
“The vast majority of patients diagnosed with T2DM have obesity, or their percentage of body fat i higher, being predominantly distributed in th a domen; howev , at the same time, obesity is considered an important risk factor in the occurr ce f T2DM [43].”
BackgroundExcess body weight: Novel insights into its roles in obesity comorbidities
Zhang, X., Ha, S., Lau, H. C.-H., & Yu, J. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.03.008 · Cited by 228
Potential Role of Seaweed Polyphenols in Cardiovascular-Associated Disorders
Gómez-Guzmán, M., Rodríguez-Nogales, A., Algieri, F., & Gálvez, J. (2018) · Marine Drugs · doi:10.3390/md16080250 · Cited by 184
“Obesity and diabetes are expected to drastically increase over the next decades [70].”
BackgroundEuropean Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity
Pasquali, R., Casanueva, F., Haluzik, M., van Hulsteijn, L., Ledoux, S., Monteiro, M. P., Salvador, J., Santini, F., Toplak, H., & Dekkers, O. M. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0893 · Cited by 188
Self-citationMoreno-Valdespino, C. A., Luna-Vital, D., Camacho-Ruiz, R. M., & Mojica, L. (2020) · Food Research International · doi:10.1016/j.foodres.2019.108905 · Cited by 168
The Role of Nutrition in COVID-19 Susceptibility and Severity of Disease: A Systematic Review
James, P. T., Ali, Z., Armitage, A. E., Bonell, A., Cerami, C., Drakesmith, H., Jobe, M., Jones, K. S., Liew, Z., Moore, S. E., et al. (2021) · The Journal of Nutrition · doi:10.1093/jn/nxab059 · Cited by 147
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22067 · Cited by 138
Obesity and cardiovascular risk
Kotsis, V., Jordan, J., Micić, D., Finer, N., Leitner, D. R., Toplak, H., Tokgözoğlu, L. S., Athyros, V. G., Elisaf, M., Filippatos, T. D., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001730 · Cited by 161
Self-citationBattista, F., Ermolao, A., van Baak, M. A., Beaulieu, K., Blundell, J. E., Busetto, L., Carraça, E. V., Encantado, J., Dicker, D., Farpour‐Lambert, N., et al. (2021) · Obesity Reviews · doi:10.1111/obr.13269 · Cited by 132
Ortega, M. A., Fraile‐Μartinez, O., Naya, I., García‐Honduvilla, N., Álvarez‐Mon, M., Buján, J., Asúnsolo, Á., & de la Torre, B. (2020) · Nutrients · doi:10.3390/nu12092749 · Cited by 139
Nanotechnology advances towards development of targeted-treatment for obesity
Sibuyi, N. R. S., Moabelo, K. L., Meyer, M., Onani, M. O., Dube, A., & Madiehe, A. M. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0554-3 · Cited by 121
PACS-2: A key regulator of mitochondria-associated membranes (MAMs)
Li, C., Li, L., Yang, M., Zeng, L., & Sun, L. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105080 · Cited by 99
Hamjane, N., Benyahya, F., Nourouti, N. G., Mechita, M. B., & Barakat, A. (2020) · Microvascular Research · doi:10.1016/j.mvr.2020.104023 · Cited by 91
Pan, X., Tan, B. C., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., Kueh, M. T. W., Khoo, C. M., Mehta, A., Majety, P., et al. (2024) · Obesity · doi:10.1002/oby.24002 · Cited by 85
“Overweight and obesity account for 44% of T2DM cases, with CVD accounting for 70% of deaths in patients with obesity [85, 86].”
BackgroundZeng, Q., Xu, J., Mu, X., Shi, Y., Fan, H., & Li, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1214334 · Cited by 66
Air Pollution, Early Life Microbiome, and Development
Vallès, Y., & Francino, M. P. (2018) · Current Environmental Health Reports · doi:10.1007/s40572-018-0215-y · Cited by 65
Haase, S., Mäurer, J., Duscha, A., Lee, D.-H., Balogh, A., Gold, R., Müller, D. N., Haghikia, A., & Linker, R. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701626 · Cited by 67
Janež, A., & Fioretto, P. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01104-z · Cited by 70
“In recent years, a new term has emerged, diabesity, reflecting the lack of weight control in patients with T2D [3] and the urgent need to find efficient strategies to address both diabetes and obesity.”
BackgroundNovelli, M., Masiello, P., Beffy, P., & Menegazzi, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218108 · Cited by 67
“Actually, weight loss per se shows beneficial effects on diabetes prevention and treatment [2], considering that a moderate weight loss obtained through lifestyle intervention in an obese population with impaired glucose tolerance could reduce the incidence of diabetes by 58% [3].”
BackgroundBorner, T., Tinsley, I. C., Doyle, R. P., Hayes, M. R., & Jonghe, B. C. D. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15647 · Cited by 49
Gestational diabesity and foetoplacental vascular dysfunction
Cornejo, M., Fuentes, G., Valero, P., Vega, S., Grismaldo, A., Toledo, F., Pardo, F., Moore‐Carrasco, R., Subiabre, M., Casanello, P. C., et al. (2021) · Acta Physiologica · doi:10.1111/apha.13671 · Cited by 54
He, X., Yu, H., Lin, S., & Li, Y. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00291-8 · Cited by 53
Prevalencia de diabetes, características epidemiológicas y complicaciones vasculares
Russo, M. P., Ratti, M. F. G., Burgos, M. A., Molaro, A. A., & Bonella, M. B. (2023) · Archivos de cardiología de México · doi:10.24875/acm.21000410 · Cited by 113
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2192865 · Cited by 54
“While recognized as a major risk factor for stroke and cardiovascular disease [4], type 2 diabetes mellitus (T2DM) [5] and”
BackgroundESI Clinical Practice Guidelines for the Evaluation and Management of Obesity In India
Madhu, S., Kapoor, N., Das, S., Nishant, R., & Sanjay, K. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.356236 · Cited by 55
“Drugs like metformin, sodium‐glucose cotransporter‐2 (SGLT2) inhibitors, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, which induce weight loss, and DPP‐4 inhibitors (weight neutral) should be preferred in the management of hyperglycemia in diabesity.[123] An observational study from India suggests that including…”
BackgroundThe role of metabolic syndrome in sudden cardiac death risk: Recent evidence and future directions
Tirandi, A., Carbone, F., Montecucco, F., & Liberale, L. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13693 · Cited by 52
Mechanisms Associated with Type 2 Diabetes as a Risk Factor for Alzheimer-Related Pathology
Su, M., Nadéri, K., Samson-Desvignes, N., Youssef, I., Fülöp, L., Bozsó, Z., Laroche, S., Delatour, B., & Davis, S. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1475-8 · Cited by 42
Nolan, R., Shannon, O. M., Robinson, N., Joel, A., Houghton, D., & Malcomson, F. C. (2020) · Nutrients · doi:10.3390/nu12051398 · Cited by 44
Mao, X., Larsen, S. B., Zachariassen, L. F., Brunse, A., Adamberg, S., Castro-Mejía, J. L., Larsen, F., Adamberg, K., Nielsen, D. S., Hansen, A. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49152-w · Cited by 60
Shraim, B. A., Moursi, M. O., Benter, I. F., Habib, A. M., & Akhtar, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.701390 · Cited by 45
Finocchietto, P. V., Perez, H., Blanco, G., Miksztowicz, V., Marotte, C., Morales, C., Peralta, J. G., Berg, G. A., Poderoso, C., Poderoso, J. J., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106028 · Cited by 45
Weight-centric treatment of type 2 diabetes mellitus
Ghusn, W., Hurtado, M. D., & Acosta, A. J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100045 · Cited by 51
“Their close and bidirectional relationship created the connotation “ diabesity ” to re fl ect this solid linkage [10].”
BackgroundSaleem, S. M., Bhattacharya, S., & Deshpande, N. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102422 · Cited by 40
„Diabesity“ – Adipositas und Typ-2-Diabetes (Update 2019)
Toplak, H., Leitner, D. R., Harreiter, J., Hoppichler, F., Wascher, T. C., Schindler, K., & Ludvik, B. H. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-018-1418-9 · Cited by 41
Self-citationBai, K., Chen, X., Song, R., Shi, W., & Shi, S. (2022) · BMC Geriatrics · doi:10.1186/s12877-022-03145-w · Cited by 47
The role of resveratrol in diabetes and obesity associated with insulin resistance
Hoca, M., Becer, E., & Vatansever, H. S. (2021) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2021.1893338 · Cited by 44
Anti-inflammatory agents as modulators of the inflammation in adipose tissue: A systematic review
Nascimento, S. S. D. C., de Queiroz, J. L. C., de Medeiros, A. F., Nunes, A. C. D. F., Piuvezam, G., Maciel, B. L. L., Passos, T. S., & Morais, A. H. D. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273942 · Cited by 40
“The treatments used for obesity depend mainly on changes in eating habits and lifestyle, being combined, when necessary, with pharmacotherapy and major surgery aiming at weight loss [27].”
BackgroundWani, K., Alfawaz, H., Alnaami, A. M., Sabico, S., Khattak, M. N. K., Al-Attas, O. S., Alokail, M. S., Alharbi, M., Chrousos, G. P., Kumar, S., et al. (2020) · Nutrients · doi:10.3390/nu12020464 · Cited by 40
“Excess body-weight (particularly obesity) is regarded as a common risk factor for diabetes [30].”
BackgroundSilveira, É. A., Rosa, L. P. D. S., Santos, A. S. E. A. D. C., Cardoso, C. K. D. S., & Noll, M. A. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17113930 · Cited by 43
“There are few studies on T2DM in obese individuals [5,6], and even fewer on those with higher obesity levels, such as class II and III [7].”
BackgroundObesity Connected Metabolic Changes in Type 2 Diabetic Patients Treated With Metformin
Aleidi, S. M., Dahabiyeh, L. A., Gu, X., Dubayee, M. A., Alshahrani, A. S., Benabdelkamel, H., Mujammami, M. H., Li, L., Aljada, A., & Rahman, A. M. A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.616157 · Cited by 40
How gut hormones shape reward: A systematic review of the role of ghrelin and GLP-1 in human fMRI
Schulz, C., Vezzani, C., & Kroemer, N. B. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114111 · Cited by 33
Gogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2356254 · Cited by 32
“…T2D share key pathophysiological mechanisms and are both associated with increased risk for (i) metabolic complications [such as hypertension, dyslipidemia, obstructive sleep apnea (OSA) and metabolic-dysfunction associated steato-tic liver disease (MASLD)] and (ii) cardiovascular disease [2,4].”
BackgroundPrevalence of diabetes, epidemiological characteristics and vascular complications
Russo, M. P., Ratti, M. F. G., Burgos, M. A., Molaro, A. A., & Bonella, M. B. (2023) · Archivos de cardiolog�a de M�xico (English ed Internet) · doi:10.24875/acme.m23000372 · Cited by 35
TNIK is a conserved regulator of glucose and lipid metabolism in obesity
Pham, T. C. P., Dollet, L., Ali, M. S., Raun, S. H., Møller, L. L. V., Jafari, A., Ditzel, N., Andersen, N. R., Fritzen, A. M., Gerhart‐Hines, Z., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf7119 · Cited by 37
Lo, C. H., O’Connor, L. M., Loi, G. W. Z., Saipuljumri, E. N., Indajang, J., Lopes, K. M., Shirihai, O. S., Grinstaff, M. W., & Zeng, J. (2024) · ACS Nano · doi:10.1021/acsnano.3c09206 · Cited by 36
Shoaib, A., Salem-Bekhit, M. M., Siddiqui, H. H., Dixit, R., Bayomi, M. A., Khalid, M., Badruddeen, B., & Shakeel, F. (2020) · 3 Biotech · doi:10.1007/s13205-019-2043-7 · Cited by 31
Farag, H. F. M., Elrewany, E. M. A., Abdel-Aziz, B. F., & Sultan, E. A. (2023) · BMC Public Health · doi:10.1186/s12889-023-15819-0 · Cited by 36
Multidisciplinary Progress in Obesity Research
Lu, X., Jin, Y., Li, D., Zhang, J., Han, J., & Li, Y. (2022) · Genes · doi:10.3390/genes13101772 · Cited by 37
“The diet also needs to match the patient’s personal food preferences, lifestyle and medical conditions [112].”
BackgroundGLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Złotek, M., Kurowska, A., Herbet, M., & Piątkowska‐Chmiel, I. (2023) · Biomedicines · doi:10.3390/biomedicines11113035 · Cited by 32
“This effect is particularly beneficial for individuals with type 2 diabetes who are overweight or obese [101].”
BackgroundMoetlediwa, M. T., Ramashia, R., Pheiffer, C., Titinchi, S. J. J., Mazibuko-Mbeje, S. E., & Jack, B. U. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814366 · Cited by 40
“diseases such as type 2 diabetes (T2D) [8], cardiovascular disease (CVD) [9], and certain types of cancers [10].”
BackgroundInfluentialAn Overview on the Therapeutic Function of Foods Enriched with Plant Sterols in Diabetes Management
Jayaraman, S., Roy, A., Vengadassalapathy, S., Sekar, R., Veeraraghavan, V., Rajagopal, P., Rengasamy, G., Mukherjee, R., Sekar, D., & Manjunathan, R. (2021) · Antioxidants · doi:10.3390/antiox10121903 · Cited by 24
“Elevated levels of these inflammatory markers induce dyslipidemia by inviting macrophages towards the adipose tissue [6,7].”
BackgroundAbnormal proliferation of gut mycobiota contributes to the aggravation of Type 2 diabetes
Bao, L., Zhang, Y., Zhang, G., Jiang, D., & Yan, D. (2023) · Communications Biology · doi:10.1038/s42003-023-04591-x · Cited by 31
TNIK’s emerging role in cancer, metabolism, and age-related diseases
Ewald, C. Y., Pulous, F. E., Lok, S. W. Y., Pun, F. W., Aliper, A., Ren, F., & Zhavoronkov, A. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.04.010 · Cited by 27
Cai, X., Ji, L., Liu, S., Wang, M., Heizhati, M., & Li, N. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s304994 · Cited by 29
“T2D is a major health problem that is growing in severity worldwide.38 The number of people with T2D aged 20–79 years was predicted to rise to 642 million by 2040.39 The prevalence of T2D is also increasing rapidly in the Western Pacific region and is expected to exceed 202 million by 2035, attributed to rapid urbaniz…”
BackgroundInfluentialBoye, K. S., Ford, J. H., Thieu, V. T., Lage, M. J., & Terrell, K. A. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01384-7 · Cited by 26
“Together, diabetes and obesity have been shown to increase mortality risk by sevenfold [13, 14].”
BackgroundArafa, E. A., Hassan, W., Murtaza, G., & Buabeid, M. A. (2020) · Journal of Diabetes Research · doi:10.1155/2020/6745873 · Cited by 33
“Data in the past two decades have revealed that obesity is one of the major risk factors of diabetes [38, 39].”
BackgroundRole of enteroendocrine hormones in appetite and glycemia
Ricardo-Silgado, M. L., MCRAE, A. N., & Acosta, A. J. (2021) · Obesity Medicine · doi:10.1016/j.obmed.2021.100332 · Cited by 32
Pourhabibi, N., Mohebbi, B., Sadeghi, R., Shakibazadeh, E., Sanjari, M., Tol, A., & Yaseri, M. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.976888 · Cited by 35
Phenolic Acids from Fruit By-Products as Therapeutic Agents for Metabolic Syndrome: A Review
Nunes, A. R., Alves, G., Falcão, A. C., Lopes, J. A., & Silva, L. R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083834 · Cited by 33
“Affecting over one billion individuals worldwide, MetS imposes a substantial burden on public health systems and significantly lowers quality of life [14].”
Bennich, B. B., Munch, L., Overgaard, D., Konradsen, H., Knop, F. K., Røder, M. E., Vilsbøll, T., & Egerod, I. (2019) · Journal of Advanced Nursing · doi:10.1111/jan.14256 · Cited by 48
“Most of our participants were overweight or obese, representing one of the most powerful risk factors of T2D (Leitner et al., 2017).”
BackgroundCai, X., Zhu, Q., Cao, Y., Liu, S., Wang, M., Wu, T., Hong, J., Ahmat, A., Aierken, X., & Li, N. (2021) · BioMed Research International · doi:10.1155/2021/5527460 · Cited by 28
Pratley, R. E., Catarig, A., Lingvay, I., Viljoen, A., Paine, A., Lawson, J., Chubb, B., Gorst‐Rasmussen, A., & Miresashvili, N. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14497 · Cited by 26
“Hence, there is a need for treatment strategies for reducing body weight, in addition to improving glycaemic control, in patients with T2D.(22) The significantly greater reductions in body weight shown with semaglutide 1.”
BackgroundInfluentialZhang, F., Yang, M., Xu, J., Hu, Y., Gao, R., Huang, K., & He, X. (2022) · Nutrients · doi:10.3390/nu14061160 · Cited by 24
“There is sufficient evidence that obesity management can delay the development of T2DM from pre-diabetes and may be beneficial to its treatment [6].”
BackgroundDanpanichkul, P., Manosroi, W., Nilsirisuk, T., & Tosukhowong, T. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1251798 · Cited by 24
“The two most essential components of metabolic syndrome are diabetes mellitus type 2 (T2DM) and obesity, which is now de fi ned by the new term “ diabesity ” (1 – 4).”
BackgroundLiu, Y., Wang, X., Podio, N. S., Wang, X., Xu, S., Jiang, S., Wei, X., Han, Y., Cai, Y., Chen, X., et al. (2023) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.13062 · Cited by 26
Carretero‐Gómez, J., Ena, J., Arévalo‐Lorido, J. C., Ripoll, J. M. S., Carrasco-Sánchez, F. J., Gómez‐Huelgas, R., Soto, M. I. P., Delgado‐Lista, J., & Martínez, P. P. (2021) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2020.06.013 · Cited by 22
Ferdous, F., Filteau, S., Schwartz, N. B., Gumede-Moyo, S., & Cox, S. E. (2022) · British Journal Of Nutrition · doi:10.1017/s0007114522001404 · Cited by 29
Lone, I. M., Nun, N. B., Ghnaim, A., Schäefer, A. S., Houri‐Haddad, Y., & Iraqi, F. A. (2023) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12311 · Cited by 23
Rodriguez-Lozada, C., Cuervo, M., Cuevas‐Sierra, A., Goñi, L., Riezu‐Boj, J. I., Navas‐Carretero, S., Milagro, F. I., & Martínez, J. A. (2019) · Nutrients · doi:10.3390/nu11061206 · Cited by 26
“Obesity is a growing public health problem worldwide [1], which is an important risk factor for inducing certain chronic diseases [2].”
BackgroundAlshahrani, S., Anwer, T., Alam, M. F., Ahmed, R. A., Khan, G., Sivakumar, S. M., Shoaib, A., Alam, P., & Azam, F. (2021) · Journal of Food Biochemistry · doi:10.1111/jfbc.13807 · Cited by 24
Ejiofor, E. U., Oyedemi, S. O., Ekeleme‐Egedigwe, C. A., Obike, C. A., Aguwamba, C., Chukwuemak, N.-A. P., Ejiofor, M., & Okwuonu, O. (2023) · Journal of Essential Oil Research · doi:10.1080/10412905.2023.2236625 · Cited by 20
Willems, I., Verbestel, V., Dumuid, D., Stanford, T., Calders, P., Lapauw, B., Bogaert, L., Blom, M. T., den Braver, N. R., van der Velde, J. H. P. M., et al. (2023) · Journal of science and medicine in sport · doi:10.1016/j.jsams.2023.11.010 · Cited by 21
Calcaterra, V., Verduci, E., Pascuzzi, M. C., Magenes, V. C., Fiore, G., Profio, E. D., Tenuta, E., Bosetti, A., Todisco, C. F., D’Auria, E., et al. (2021) · Nutrients · doi:10.3390/nu13082805 · Cited by 24
Greiner, W., Patel, K., Crossman-Barnes, C.-J., Rye-Andersen, T. V., Hvid, C. A., & Vandebrouck, T. (2021) · PharmacoEconomics - Open · doi:10.1007/s41669-020-00253-4 · Cited by 19
“Similarly, weight loss is not recognised as a patient-relevant endpoint even though obesity is known to be the main risk factor for a number of non-communicable diseases such as cardiovascular disease, T2DM, hypertension, coronary heart disease, and certain cancers [79].”
BackgroundBawady, N., Aldafrawy, O., ElZobair, E. M., Suliman, W., Alzaabi, A., & Ahmed, S. H. (2021) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000519444 · Cited by 19
Phytanic acid, an inconclusive phytol metabolite: A review
Islam, M. T., Bhuia, M. S., de Lima, J. P. M., Maia, F. P. A., Ducati, A. B. H., & Coutinho, H. D. M. (2023) · Current Research in Toxicology · doi:10.1016/j.crtox.2023.100120 · Cited by 24
Yi, X., Cai, X., Wang, S., & Xiao, Y. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11013 · Cited by 29
Stojchevski, R., Chandrasekaran, P., Hadzi‐Petrushev, N., Mladenov, M. I., & Avtanski, D. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147849 · Cited by 20
“Obesity is a significant risk factor for the development and progression of T2DM [3].”
BackgroundSGLT2 Inhibitors and the Mechanisms Involved in Weight Loss
Feder, D., Gouveia, M. R. D. F. V., Govato, T. C. P., & Nassis, C. D. Z. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00236-3 · Cited by 22
Leptin Reduces Plin5 m6A Methylation through FTO to Regulate Lipolysis in Piglets
Wei, D., Sun, Q., Li, Y., Li, C., Li, X., & Sun, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910610 · Cited by 20
“Given the strong association between the excess of weight and T2D, the focus of a suitable antidiabetic treatment of obese patients should at least be the prevention of additional weight gain [42].”
BackgroundSex differences in white adipose tissue expansion: emerging molecular mechanisms
Bond, S. T., Calkin, A. C., & Drew, B. G. (2021) · Clinical Science · doi:10.1042/cs20210086 · Cited by 18
Nagao, K., Inoue, N., Suzuki, K., Shimizu, T., & Yanagita, T. (2021) · Metabolites · doi:10.3390/metabo12010026 · Cited by 18
Kashif, R. R., D'Cunha, N. M., Mellor, D. D., Alexopoulos, N. I., Sergi, D., & Naumovski, N. (2022) · Medicina · doi:10.3390/medicina58020300 · Cited by 28
“The prevalence of obesity is increasing worldwide and continues to represent a major health concern [1], affecting over a third of the global population [2].”
BackgroundMemelink, R. G., Hummel, M., Hijlkema, A., Streppel, M. T., Bautmans, I., Weijs, P. J. M., Berk, K. A., & Tieland, M. (2023) · Diabetic Medicine · doi:10.1111/dme.15096 · Cited by 23
Han, J., Chen, Y., Xu, X., Li, Q., Xiang, X., Shen, J., & Ma, X. (2024) · ACS Nano · doi:10.1021/acsnano.4c00403 · Cited by 18
Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity
Horváth, L., Mráz, M., Jude, E. B., & Haluzík, M. (2024) · Drugs · doi:10.1007/s40265-024-02029-0 · Cited by 22
“…as obesity has been linked to the development of numerous comorbidities, including hypertension [5], dyslipidemia [6], type 2 diabetes mellitus [7, 8], atrial fibrillation [9], non-alcoholic fatty liver disease (NAFLD) [10], sleep apnea syndrome [11], cancer [12] and a wide spectrum of other…”
BackgroundYu, J., Loh, K., Yang, H.-Q., Du, M.-R., Wu, Y.-X., Liao, Z., Guo, A., Yang, Y., Chen, B., Zhao, Y., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03728-8 · Cited by 18
Marcinkiewicz, K., Horodnicka‐Józwa, A., Jackowski, T., Strączek, K., Biczysko‐Mokosa, A., Walczak, M., & Petriczko, E. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.992264 · Cited by 20
“In the future they are possible candidates for combined pharmacological or bariatric treatment (50).”
BackgroundThe impact of high-glucose or high-fat diets on the metabolomic profiling of mice
Xie, D., Zhang, Y., Guo, Y., Xue, X., Zhao, S., Geng, C., Li, Y., Yang, R., Gan, Y., Li, H., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1171806 · Cited by 21
“Obesity has been highly related to detrimental glucose profiles, and leads to the development of type 2 diabetes (T2DM) (13).”
BackgroundHarrold, J. A., Hill, S., Radu, C. C. P., Thomas, P., Thorp, P., Hardman, C. A., Christiansen, P., & Halford, J. C. G. (2023) · Obesity · doi:10.1002/oby.23796 · Cited by 19
“Overweight and obesity are associated with a plethora of weightrelated complications such as type 2 diabetes and cardiovascular disease [2, 3], as well as poor mental health and quality of life [4, 5].”
BackgroundDiabetes exacerbates inflammatory bowel disease in mice with diet-induced obesity
Francis, K. L., Alonge, K. M., Pacheco, M. C., HU, S. J. W., KRUTZSCH, C. A., Morton, G. J., Schwartz, M. W., & Scarlett, J. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i33.4991 · Cited by 17
“T2D is strongly associated with obesity, with the majority of T2D patients being either overweight or obese[12,13].”
The impact of poor metabolic health on aggressive breast cancer: adipose tissue and tumor metabolism
Sankofi, B. M., Valencia-Rincón, E., Sekhri, M., Ponton-Almodovar, A. L., Bernard, J. J., & Wellberg, E. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1217875 · Cited by 18
“Excess body weight is a prominent risk factor for T2D; approximately 90% of people with T2D have overweight or obesity (6, 7).”
BackgroundMesenchymal Stem Cells Anti-Inflammatory Activity in Rats: Proinflammatory Cytokines
Petryk, N., & Shevchenko, O. (2020) · Journal of Inflammation Research · doi:10.2147/jir.s256932 · Cited by 21
Metadata
- Authors
- Leitner, D. R., Frühbeck, G., Yumuk, V., Schindler, K., Micic, D., Woodward, E., & Toplak, H.
- Affiliations
- University of Graz (AT)
- Instituto de Salud Carlos III (ES)
- Istanbul University-Cerrahpaşa (TR)
- Medical University of Vienna (AT)
- European Association for the Study of Obesity (GB)
- Venue
- Obesity Facts
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 10
- Issue
- 5
- Pages
- 483-492
- ISSN
- 1662-4025 (ISSN-L)
- 1662-4033
- PMC
- PMC5741209
- OpenAlex
- W2762120405
- Cited by
- 431
- References
- 76
- Citations by year
- 2026: 16 · 2025: 51 · 2024: 67 · 2023: 80 · 2022: 76 · 2021: 68 · 2020: 51 · 2019: 14 · 2018: 8
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
- Locations
- Obesity Facts (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- obesity, type 2 diabetes, diabesity, body composition, weight loss, lifestyle intervention, pharmacotherapy, bariatric surgery, glycemic control
- MeSH terms
- Adult, Child, Combined Modality Therapy, Diabetes Mellitus, Type 2, Diet, Health Services Needs and Demand, Humans, Life Style, Obesity, Exercise, Comorbidity, Anti-Obesity Agents, Bariatric Surgery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.